Loading clinical trials...
Loading clinical trials...
A Phase 1, 2-Part, Multicenter, Open-Label, First-in-Human Study of the Anti-Ly6E Exatecan Antibody-Drug Conjugate M7437 in Participants With Advanced Solid Tumors
Conditions
Interventions
M7437
M7437
Locations
9
United States
Yale University - Yale University School of Medicine
New Haven, Connecticut, United States
Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center
Huntersville, North Carolina, United States
NEXT Houston
Galveston, Texas, United States
NEXT Oncology - PARENT
San Antonio, Texas, United States
Princess Margaret Cancer Centre
Toronto, Canada
BC Cancer - Vancouver - BC Cancer Agency
Vancouver, Canada
Start Date
February 13, 2026
Primary Completion Date
September 20, 2028
Completion Date
March 28, 2029
Last Updated
April 21, 2026
NCT07403721
NCT06898450
NCT05719558
NCT07029399
NCT04826341
NCT06819735
Lead Sponsor
EMD Serono Research & Development Institute, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions